Blackstone Inc’s Praxis Precision Medicines PRAX Stock Holding History

Blackstone Inc’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-70,273	Closed	-$1.57M	–	187
2023 Q4	$1.57M	Sell	70,273 -1	-0%	-$18	0.01%	105
2023 Q3	$1.8M	Hold	70,274	–	–	0.01%	111
2023 Q2	$1.21M	Hold	70,274	–	–	0.01%	118
2023 Q1	$854K	Sell	70,274 -256,000	-78%	-$10.8M	﹤0.01%	127
2022 Q4	$11.6M	Hold	326,274	–	–	0.04%	62
2022 Q3	$11.1M	Hold	326,274	–	–	0.04%	65
2022 Q2	$12M	Hold	326,274	–	–	0.04%	79
2022 Q1	$50M	Hold	326,274	–	–	0.13%	62
2021 Q4	$96.4M	Sell	326,274 -29,770	-8%	-$8.73M	0.24%	51
2021 Q3	$98.7M	Sell	356,044 -30,722	-8%	-$8.33M	0.22%	56
2021 Q2	$106M	Sell	386,766 -180,000	-32%	-$64.5M	0.24%	48
2021 Q1	$278M	Hold	566,766	–	–	0.55%	29
2020 Q4	$468M	Buy	+566,766	New	+$331M	1.64%	10

Other funds holding PRAX

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Blackstone Inc's PRAX Position: Q1 2024 in Review

Blackstone Inc sold out of Praxis Precision Medicines (PRAX) in Q1 2024, closing a stake of 70,273 shares — an estimated $1.57M sold.

Blackstone Inc first reported a position in PRAX in Q4 2020 and held it in 13 quarters. The position peaked at $468M in Q4 2020. 111 funds tracked by Wall St. Rank hold PRAX as of Q1 2024.

Blackstone Inc reported no remaining Praxis Precision Medicines position as of Q1 2024 after selling out during the quarter.
Blackstone Inc sold 70,273 Praxis Precision Medicines shares in Q1 2024, an estimated $1.57M.
Blackstone Inc first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 13 quarters.
Blackstone Inc's Praxis Precision Medicines position peaked at $468M in Q4 2020.
111 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2024.

Based on Blackstone Inc's 13F filing for Q1 2024, filed 15 May 2024.